112
Views
4
CrossRef citations to date
0
Altmetric
Articles

Synthesis, cytotoxicity, apoptosis and cell cycle arrest of a monoruthenium(II)-substituted Dawson polyoxotungstate

, , &
Pages 633-644 | Received 19 Apr 2018, Accepted 16 Nov 2018, Published online: 11 Feb 2019
 

Abstract

By 5-h reaction of cis-[RuIICl2(DMSO)4] (M2) with K102-P2W17O61] (M3) in ice-cooled, HCl-acidic aqueous solution, a water-soluble 1:2-type diamagnetic ruthenium(II) complex of formula K18[RuII(DMSO)2(P2W17O61)2]·35H2O (M1) was unexpectedly obtained as an analytically pure, homogeneous tan-colored solid, in which two DMSO ligands are coordinated to the ruthenium(II) atom. The cytotoxic potential of the complex was tested on C33A, DLD-1, and HepG-2 cancer cells and human normal embryonic lung fibroblasts cell MRC-5; the viability of the treated cells was evaluated by MTT assay. The mode of cell death was assessed by morphological study of DNA damage and apoptosis assays. Compound M1 induced cell death in a dose-dependent manner, and the mode of cell death was essentially apoptosis though necrosis was also noticed. Cell cycle analysis by flow cytometry indicated that M1 caused cell cycle arrest and accumulated cells in S phase.

Additional information

Funding

This work was supported by the National Natural Science Foundation of China (No. 21701120), the Natural Science Fund of Shanxi Province (No. 201601D202024) and Doctor Fund of Taiyuan University of Science and Technology (No. 20172005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.